Clinical Outcomes and Safety of Secukinumab in Thai Patients with Plaque Psoriasis: A 16-Week, Multicenter, Retrospective, Real-World Study

• المؤلفون الرئيسيون: Bensachee Pattamadilok, Pravit Asawanonda, Charoen Choonhakarn, Chanidapa Wongtada, Ploysyne Rattanakaemakorn, Natta Rajatanavin
• مؤلفون آخرون: Ramathibodi Hospital
• التنسيق: مقال
• منشور في: 2022
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://repository.li.mahidol.ac.th/handle/123456789/74821
• المؤسسة: Mahidol University

Background: Secukinumab, an interleukin 17A-inhibitor approved for the treatment of moderate-to-severe plaque psoriasis, has been well-studied in phase II and III trials and shown to have a sustained high-level of clinical efficacy with good safety profile and positive impact on patients' quali...